The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus

被引:0
作者
Dalan, Rinkoo [1 ,2 ,3 ]
Liuh Ling, Goh [1 ]
机构
[1] Tan Tock Seng Hosp, Singapore, Singapore
[2] NTU Lee Kong Chian Sch Med, Singapore, Singapore
[3] Yong Loo Lin Sch Med, Singapore, Singapore
基金
英国医学研究理事会;
关键词
Haptoglobin; haptoglobin polymorphism; diabetes mellitus; METABOLICALLY HEALTHY OBESE; CARDIOVASCULAR-DISEASE EVENTS; NORMAL-WEIGHT PEOPLE; INSULIN-RESISTANCE; ADIPOSE-TISSUE; ADIPONECTIN LEVELS; GROWTH-FACTORS; RISK-FACTORS; ASSOCIATION; CHEMERIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and background Haptoglobin (Hp) is considered to be an antioxidant and protective against cardiovascular complications. Polymorphisms in the Hp gene interact with diabetes mellitus to affect the risk of vascular complications.Methods We review the updated literature about the protean role of Hp and Hp genotypes spanning genomics, molecular, translational and clinical studies. We searched Pubmed, SCOPUS and Google Scholar for all articles using the keywords: haptoglobin and/or haptoglobin polymorphism and diabetes. We review the diverse Hp genotypes, phenotypes and the impact on diabetes complications, including lessons from animal models and in vitro models. We describe the clinical studies on the associations of Hp genotypes with vascular complications in type 1 and type 2 diabetes comprehensively. We review the studies looking at vitamin E supplementation in a personalized manner in Hp2-2 diabetes individuals.Results and conclusion Hp genotypes have evolved as a result of deletions in the traditional Hp genes. The Hp genotypes have been associated with microvascular and macrovascular complications in type 1 diabetes mellitus but the association in type 2 diabetes is more consistent with cardiovascular complications. A preferential benefit of vitamin E and other antioxidants in the Hp2-2 genotype for cardiovascular complications in type 2 diabetes has been seen presumably secondary to interaction with high-density lipoprotein function. Hence, the Hp genotype can be used to personalize antioxidant therapeutics in diabetes patients. These results need to be corroborated in large, global, pragmatic, prospective, cardiovascular outcome trials in type 2 diabetes patients.
引用
收藏
页码:1502 / 1519
页数:18
相关论文
共 48 条
  • [1] Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: Adipose depot specificity and gender dimorphism
    Alfadda, Assim A.
    Sallam, Reem M.
    Chishti, Muhammad Azhar
    Moustafa, Amr S.
    Fatma, Sumbul
    Alomaim, Waleed S.
    Al-Naami, Mohammed Y.
    Bassas, Abdulelah F.
    Chrousos, George P.
    Jo, Hyunsun
    [J]. MOLECULES AND CELLS, 2012, 33 (06) : 591 - 596
  • [2] rs1501299 Polymorphism in the Adiponectin Gene and Their Association with Total Adiponectin Levels, Insulin Resistance and Metabolic Syndrome in Obese Subjects
    Antonio de Luis, Daniel
    Izaola, Olatz
    de la Fuente, Beatriz
    Primo, David
    Fernandez Ovalle, Hilda
    Romero, Enrique
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2016, 69 (3-4) : 226 - 231
  • [3] Reduced Expression of Chemerin in Visceral Adipose Tissue Associates with Hepatic Steatosis in Patients with Obesity
    Bekaert, Marlies
    Ouwens, D. Margriet
    Hoerbelt, Tina
    Van de Velde, Frederique
    Fahlbusch, Pia
    de Wiza, Daniella Herzfeld
    Van Nieuwenhove, Yves
    Calders, Patrick
    Praet, Marleen
    Hoorens, Anne
    Geerts, Anja
    Verhelst, Xavier
    Kaufman, Jean-Marc
    Lapauw, Bruno
    [J]. Obesity, 2016, 24 (12) : 2544 - 2552
  • [4] Chemerin is a novel adipokine associated with obesity and metabolic syndrome
    Bozaoglu, Kiymet
    Bolton, Kristy
    McMillan, Janine
    Zimmet, Paul
    Jowett, Jeremy
    Collier, Greg
    Walder, Ken
    Segal, David
    [J]. ENDOCRINOLOGY, 2007, 148 (10) : 4687 - 4694
  • [5] Adipose Tissue Dysfunction in Nascent Metabolic Syndrome
    Bremer, Andrew A.
    Jialal, Ishwarlal
    [J]. JOURNAL OF OBESITY, 2013, 2013
  • [6] Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women
    Caleyachetty, Rishi
    Thomas, G. Neil
    Toulis, Konstantinos A.
    Mohammed, Nuredin
    Gokhale, Krishna M.
    Balachandran, Kumarendran
    Nirantharakumar, Krishnarajah
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (12) : 1429 - 1437
  • [7] Higher mortality in metabolically obese normal-weight people than in metabolically healthy obese subjects in elderly Koreans
    Choi, Kyung Mook
    Cho, Hyun Joo
    Choi, Hae Yoon
    Yang, Sae Jeong
    Yoo, Hye Jin
    Seo, Ji A.
    Kim, Sin Gon
    Baik, Sei Hyun
    Choi, Dong Seop
    Kim, Nan Hee
    [J]. CLINICAL ENDOCRINOLOGY, 2013, 79 (03) : 364 - 370
  • [8] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [9] Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes
    Cnop, Miriam
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2008, 36 : 348 - 352
  • [10] Lean, but not healthy: the "metabolically obese, normal-weight' phenotype
    Ding, Cherlyn
    Chan, Zhiling
    Magkos, Faidon
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2016, 19 (06) : 408 - 417